The short-term clinical investigation of ticagrelor in reducing cardiovascular MACEs for elective PCI patients with stable coronary heart disease.

Trial Profile

The short-term clinical investigation of ticagrelor in reducing cardiovascular MACEs for elective PCI patients with stable coronary heart disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Coronary artery disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 21 Aug 2016 Status changed from recruiting to completed.
    • 19 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top